BCRX · NASDAQ
BioCryst Pharmaceuticals (BCRX) Stock Price & Fundamentals
BioCryst Pharmaceuticals (BCRX) closed at $709.33 on Oct 9, 2026, up 0.33% from the previous close of $707.03.
Share price, past year
1Y +7.34%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $709.33 |
| Sep 30, 2026 | $718.38 |
| Aug 31, 2026 | $731.04 |
| Jul 31, 2026 | $744.72 |
| Jun 30, 2026 | $782.68 |
| May 29, 2026 | $828.55 |
| Apr 30, 2026 | $815.84 |
| Mar 31, 2026 | $804.69 |
| Feb 27, 2026 | $798.75 |
| Jan 30, 2026 | $746.21 |
| Dec 31, 2025 | $708.74 |
| Nov 28, 2025 | $691.17 |
| Oct 31, 2025 | $699.48 |
Key statistics
- Market cap
- $181.07B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.49
- Revenue (TTM)
- $940.61M
- Net income (TTM)
- −$384.67M
- Shares outstanding
- 255.3M
- Dividend yield
- —
- 52-week range
- $660.85 – $853.24
BioCryst Pharmaceuticals's market cap is $181.07B, based on a share price of $709.33 and 255.3M shares outstanding as of Jun 30, 2026.
Financials
BioCryst Pharmaceuticals reported revenue of $874.84M for fiscal 2025, up 94.10% from fiscal 2024.
BioCryst Pharmaceuticals earned net income of $263.86M in fiscal 2025, a net margin of 30.2%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $874.84M | +94.1% | $263.86M | 30.2% | $1.21 | — |
| FY2024ended Dec 31, 2024 | $450.71M | +36.0% | −$88.88M | −19.7% | −$0.43 | — |
| FY2023ended Dec 31, 2023 | $331.41M | +22.4% | −$226.54M | −68.4% | −$1.18 | — |
| FY2022ended Dec 31, 2022 | $270.83M | +72.3% | −$247.12M | −91.2% | −$1.33 | — |
| FY2021ended Dec 31, 2021 | $157.17M | +782.4% | −$184.06M | −117.1% | −$1.03 | — |
| FY2020ended Dec 31, 2020 | $17.81M | −63.5% | −$182.81M | −1,026.4% | −$1.09 | — |
| FY2019ended Dec 31, 2019 | $48.84M | +136.5% | −$108.90M | −223.0% | −$940.00 | −$89.93M |
| FY2018ended Dec 31, 2018 | $20.65M | −18.0% | −$101.25M | −490.3% | −$0.98 | −$92.93M |
| FY2017ended Dec 31, 2017 | $25.19M | −4.4% | −$65.78M | −261.2% | −$0.78 | −$41.47M |
| FY2016ended Dec 31, 2016 | $26.35M | — | −$55.14M | −209.3% | −$0.75 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $218.25M | $78.40M | $0.30 |
| Q1 FY2026ended Mar 31, 2026 | $156.41M | −$721.81M | −$2.98 |
| Q4 FY2025ended Dec 31, 2025 | $406.56M | $245.85M | $1.13 |
| Q3 FY2025ended Sep 30, 2025 | $159.40M | $12.90M | $0.06 |
| Q2 FY2025ended Jun 30, 2025 | $163.35M | $5.09M | $0.02 |
| Q1 FY2025ended Mar 31, 2025 | $145.53M | $32.00K | $0.00 |
| Q4 FY2024ended Dec 31, 2024 | $131.53M | −$26.80M | −$0.13 |
| Q3 FY2024ended Sep 30, 2024 | $117.09M | −$14.03M | −$0.07 |
Company profile
- Name
- BioCryst Pharmaceuticals, Inc.
- Ticker
- BCRX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 4505 Emperor Boulevard, Suite 200, Durham, NC 27703
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000882796
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 29, 2026
- Jun 12, 2026
- May 6, 2026
- May 6, 2026
- May 4, 2026
- Feb 26, 2026
Frequently asked questions
What is BioCryst Pharmaceuticals's stock price?
BioCryst Pharmaceuticals (BCRX) closed at $709.33 on Oct 9, 2026, up 0.33% from the previous close of $707.03.
What is BioCryst Pharmaceuticals's market cap?
BioCryst Pharmaceuticals's market cap is $181.07B, based on a share price of $709.33 and 255.3M shares outstanding as of Jun 30, 2026.
How much revenue does BioCryst Pharmaceuticals make?
BioCryst Pharmaceuticals reported revenue of $874.84M for fiscal 2025, up 94.10% from fiscal 2024.
Does BioCryst Pharmaceuticals pay a dividend?
BioCryst Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BioCryst Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures